Pediatric Cardiology

, Volume 34, Issue 4, pp 826–834

Cranial Irradiation as an Additional Risk Factor for Anthracycline Cardiotoxicity in Childhood Cancer Survivors: An Analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study

  • David C. Landy
  • Tracie L. Miller
  • Stuart R. Lipsitz
  • Gabriela Lopez-Mitnik
  • Andrea S. Hinkle
  • Louis S. Constine
  • M. Jacob Adams
  • Steven E. Lipshultz
Original Article

Abstract

Anthracycline-treated childhood cancer survivors experience cardiac damage that results in decreased left ventricular (LV) mass, leading to increased LV wall stress, which underlies their greater risk of cardiomyopathy. Many of these survivors also are at risk of growth hormone (GH) abnormalities from cranial irradiation exposure, although it is unknown whether such exposure is associated with cardiotoxicity. Echocardiograms and insulin-like growth factor-1 (IGF-1), a marker of GH, were measured in 130 anthracycline-treated childhood cancer survivors, 59 of whom had been exposed to cranial irradiation, a mean 10 years after their cancer diagnosis. Echocardiographic parameters and IGF-1 were standardized relative to age or body surface area using data from sibling control subjects and expressed as the percentage difference from normal values. The results showed that after adjustment for other risk factors, survivors exposed to cranial irradiation had an additional 12 % decrease in LV mass compared with unexposed survivors (P < 0.01) and an additional 3.6 % decrease in LV dimension (P = 0.03). Survivors exposed to cranial irradiation also had a 30.8 % decrease in IGF-1 relative to normal values, which was greater than the 10.5 % decrease in unexposed survivors (P < 0.01). The above findings led us to conclude that in anthracycline-treated childhood cancer survivors a mean 10 years after their diagnosis, those with cranial irradiation exposure had significantly greater decreases in LV mass and dimension. Because cranial irradiation also was associated with decreased IGF-1, it is possible that GH deficiencies mediated this effect, suggesting that GH replacement therapy may help to prevent the development of cardiotoxicity.

Keywords

Anthracyclines Cancer Cardiomyopathy Cranial irradiation Survivors 

Supplementary material

246_2012_539_MOESM1_ESM.doc (277 kb)
Supplementary material 1 (DOC 277 kb)
246_2012_539_MOESM2_ESM.mp4 (6 mb)
This video provides a step-by-step review of how the LV parameter values of the survivors were standardized relative to body-surface area or age using the sibling control data and then compared by cranial irradiation exposure group. (MP4 6,112 kb)
246_2012_539_MOESM3_ESM.mp4 (5.5 mb)
This video provides a step-by-step review of how the IGF-1 values of the survivors were standardized relative to age using the sibling control data, compared by cranial irradiation exposure group, and examined for an association with LV parameters among the cranial irradiation exposed group. (MP4 5,586 kb)

References

  1. 1.
    Andreassen M, Faber J, Kjaer A, Petersen CL, Kristensen LØ (2011) Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study. Pituitary 14:1–10PubMedCrossRefGoogle Scholar
  2. 2.
    Bowers DC, Adhikari S, El-Khashab YM, Gargan L, Oeffinger KC (2009) Survey of long-term follow-up programs in the United States for survivors of childhood brain tumors. Pediatr Blood Cancer 53:1295–1301PubMedCrossRefGoogle Scholar
  3. 3.
    Capalbo D, Lo Vecchio A, Farina V, Spinelli L, Palladino A, Tiano C, Lettiero T, Lombardi G, Colao A, Salerno M (2009) Subtle alterations of cardiac performance in children with growth hormone deficiency: results of a two-year prospective, case–control study. J Clin Endocrinol Metab 94:3347–3355PubMedCrossRefGoogle Scholar
  4. 4.
    Colan SD, Parness IA, Spevak PJ, Sanders SP (1992) Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol 19:619–629PubMedCrossRefGoogle Scholar
  5. 5.
    Darzy KH, Shalet SM (2009) Hypopituitarism following radiotherapy revisited. Endocr Dev 15:1–24PubMedCrossRefGoogle Scholar
  6. 6.
    Dorup I, Levitt G, Sullivan I, Sorensen K (2004) Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart 90:1214–1216PubMedCrossRefGoogle Scholar
  7. 7.
    Dreifuss P (2004) Cardiac effects of growth hormone. Circulation 109:e332PubMedCrossRefGoogle Scholar
  8. 8.
    Follin C, Thilen U, Osterberg K, Bjork J, Erfurth EM (2010) Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab 95:3726–3735PubMedCrossRefGoogle Scholar
  9. 9.
    Hinkle AS, Proukou C, French CA, Kozlowski AM, Constine LS, Lipsitz SR, Miller TL, Lipshultz SE (2004) A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses. Pediatrics 113:1141–1145PubMedGoogle Scholar
  10. 10.
    Kremer LCM, van der Pal JHJ, Offringa M, van Dalen EC, Voute PA (2002) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13:819–829PubMedCrossRefGoogle Scholar
  11. 11.
    Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 15:1544–1552PubMedGoogle Scholar
  12. 12.
    Landy DC, Miller TL, Lopez-Mitnik G, Lipsitz SR, Hinkle AS, Constine LS, French CA, Rovitelli AM, Adams MJ, Lipshultz SE (2012) Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors study. Am Heart J 163:295–301PubMedCrossRefGoogle Scholar
  13. 13.
    Link K, Moëll C, Garwicz S, Cavallin-Ståhl E, Björk J, Thilén U, Ahrén B, Erfurth EM (2004) Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab 89:5003–5012PubMedCrossRefGoogle Scholar
  14. 14.
    Lipshultz SE, Adams MJ (2010) Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol 28:1276–1281PubMedCrossRefGoogle Scholar
  15. 15.
    Lipshultz SE, Colan SD (2004) Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol 22:769–773PubMedCrossRefGoogle Scholar
  16. 16.
    Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815PubMedCrossRefGoogle Scholar
  17. 17.
    Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738–1743PubMedCrossRefGoogle Scholar
  18. 18.
    Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, Schluchter MD, Colan SD (2001) Reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function: the prospective P2C2 HIV study. Circulation 104:310–316PubMedCrossRefGoogle Scholar
  19. 19.
    Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD (2005) Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23:2629–2636PubMedCrossRefGoogle Scholar
  20. 20.
    Lipshultz SE, Vlach SA, Lipsitz SR, Sallan SE, Schwartz ML, Colan SD (2005) Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 115:1613–1622PubMedCrossRefGoogle Scholar
  21. 21.
    Lipshultz SE, Landy DC, Lopez-Mitnik G, Lipsitz SR, Hinkle AS, Constine LS, French CA, Rovitelli AM, Proukou C, Adams MJ, Miller TL (2012) Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 30:1050–1057PubMedCrossRefGoogle Scholar
  22. 22.
    Maison P, Chanson P (2003) Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 25:2648–2652CrossRefGoogle Scholar
  23. 23.
    Mariotto AB, Rowland JH, Yabroff KR, Scoppa S, Hachey M, Ries L, Feuer EJ (2009) Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 18:1033–1040PubMedCrossRefGoogle Scholar
  24. 24.
    McElhinney DB, Colan SD, Moran AM, Wypij D, Lin M, Majzoub JA, Crawford EC, Bartlett JM, McGrath EA, Newburger JW (2004) Recombinant human growth hormone treatment for dilated cardiomyopathy in children. Pediatrics 114:e452–e458PubMedCrossRefGoogle Scholar
  25. 25.
    Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, Robison LL, Yasui Y (2008) Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivors Study. J Natl Cancer Inst 100:1368–1379PubMedCrossRefGoogle Scholar
  26. 26.
    Miller TL, Lipsitz SR, Lopez-Mitnik G, Hinkle AS, Constine LS, Adams MJ, French C, Proukou C, Rovitelli A, Lipshultz SE (2010) Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 19:2013–2022PubMedCrossRefGoogle Scholar
  27. 27.
    Minczykowski A, Gryczynska M, Ziemnicka K, Czepczynski R, Sowinski J, Wysocki H (2005) The influence of growth hormone (GH) therapy on cardiac performance in patients with childhood onset GH deficiency. Growth Horm IGF Res 15:156–164PubMedCrossRefGoogle Scholar
  28. 28.
    Möller TR, Garwicz S, Barlow L, Falck Winther J, Glattre E, Olafsdottir G, Olsen JH, Perfekt R, Ritvanen A, Sankila R, Tulinius H (2001) Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 19:3173–3181PubMedGoogle Scholar
  29. 29.
    Mulder RL, Kremer LC, van Santen HM, Ket JL, van Trotsenburg AS, Koning CC, Schouten-van Meeteren AY, Caron HN, Neggers SJ, van Dalen EC (2009) Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treat Rev 35:616–632PubMedCrossRefGoogle Scholar
  30. 30.
    Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b46067CrossRefGoogle Scholar
  31. 31.
    Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582PubMedCrossRefGoogle Scholar
  32. 32.
    Oeffinger KC, Adams-Huet B, Victor RG, Church TS, Snell PG, Dunn AL, Eshelman-Kent DA, Ross R, Janiszewski PM, Turoff AJ, Brooks S, Vega GL (2009) Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 27:3698–3704PubMedCrossRefGoogle Scholar
  33. 33.
    Olsson DS, Buchfelder M, Schlaffer S, Bengtsson BA, Jakobsson KE, Johannsson G, Nilsson AG (2009) Comparing progression of nonfunctioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. Eur J Endocrinol 161:663–669PubMedCrossRefGoogle Scholar
  34. 34.
    Ozdemir O, Abaci A, Hizli S, Razi CH, Akelma AZ, Kocak M, Kislal FM (2003) Cardiac functions in children with growth hormone deficiency before and during growth hormone-replacement therapy. Pediatr Cardiol 32:766–771CrossRefGoogle Scholar
  35. 35.
    Renehan AG, Brennan BM (2008) Acromegaly, growth hormone, and cancer risk. Best Pract Res Clin Endocrinol Metab 22:639–657PubMedCrossRefGoogle Scholar
  36. 36.
    Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, Skinner R, Stevens MC, Hawkins MM (2010) Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304:172–179PubMedCrossRefGoogle Scholar
  37. 37.
    Rutter MM, Rose SR (2007) Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr 19:480–487PubMedCrossRefGoogle Scholar
  38. 38.
    Salerno M, Esposito V, Farina V, Radetti G, Umbaldo A, Capalbo D, Spinelli L, Muzzica S, Lombardi G, Colao A (2006) Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. J Clin Endocrinol Metab 91:1288–1295PubMedCrossRefGoogle Scholar
  39. 39.
    Sanchez J, Carrillo A, Scully RE, Preble S, Lipshultz SE (2009) Cardiac effects of growth hormone treatment in pediatric populations. In: Brataas J, Nanstveit V (eds) Handbook of cardiovascular research. Nova Publishing, Hauppauge, pp 271–284Google Scholar
  40. 40.
    Silber JH (2005) Role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatr Blood Cancer 44:607–613PubMedCrossRefGoogle Scholar
  41. 41.
    Silverman LB, Stevenson KE, O’Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O’Holleran EW, Neuberg DS, Cohen HJ, Sallan SE (2010) Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia 24:320–334PubMedCrossRefGoogle Scholar
  42. 42.
    Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID (2003) Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 97:1991–1998PubMedCrossRefGoogle Scholar
  43. 43.
    Talvensaari KK, Lanning M, Tapanainen P, Knip M (1996) Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab 81:3051–3055PubMedCrossRefGoogle Scholar
  44. 44.
    Trachtenberg BH, Landy DC, Franco VI, Henkel JM, Pearson EJ, Miller TL, Lipshultz SE (2011) Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 32:342–353PubMedCrossRefGoogle Scholar
  45. 45.
    Tukenova M, Guibout C, Oberlin O, Doyon F, Mousannif A, Haddy N, Guérin S, Pacquement H, Aouba A, Hawkins M, Winter D, Bourhis J, Lefkopoulos D, Diallo I, de Vathaire F (2010) Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28:1308–1315PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • David C. Landy
    • 1
  • Tracie L. Miller
    • 1
    • 2
    • 5
  • Stuart R. Lipsitz
    • 3
  • Gabriela Lopez-Mitnik
    • 1
  • Andrea S. Hinkle
    • 4
  • Louis S. Constine
    • 6
  • M. Jacob Adams
    • 7
  • Steven E. Lipshultz
    • 1
    • 2
    • 5
  1. 1.Division of Pediatric Clinical Research, Department of Pediatrics and Bachelor Children’s Research InstituteUniversity of Miami Miller School of MedicineMiamiUSA
  2. 2.Sylvester Comprehensive Cancer Center, University of Miami Miller School of MedicineMiamiUSA
  3. 3.Brigham and Women’s HospitalBostonUSA
  4. 4.Department of PediatricsUniversity of Rochester School of Medicine and DentistryRochesterUSA
  5. 5.Children’s Heart Center, Holtz Children’s Hospital of the Jackson Health SystemMiamiUSA
  6. 6.Department of Radiation OncologyUniversity of Rochester School of Medicine and DentistryRochesterUSA
  7. 7.Department of Public Health SciencesUniversity of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations